Ductal carcinoma in situ (DCIS) remains one of the most debated and evolving areas in breast cancer care. In this session, Dr. Laura Esserman will provide an up-to-date review of the evidence on the diagnosis, risk stratification, and management of DCIS. Participants will explore emerging data on active surveillance, concerns about overtreatment, imaging advances, and personalized decision-making. Through case-based discussion, this interactive session will help clinicians navigate nuanced conversations and align treatment approaches with evolving science and patient-centered care.

Laura J. Esserman, MD, MBA is an internationally recognized breast surgeon, oncologist, and visionary in personalized medicine at the University of California, San Francisco, where she has served as Director of the UCSF Breast Care Center since 1996. A Harvard undergraduate and Stanford-trained physician, Dr. Esserman is Principal Investigator of the groundbreaking I-SPY clinical trials and founder of the WISDOM Study, a landmark national initiative redefining personalized breast cancer screening. A fierce advocate for reducing overdiagnosis and overtreatment, she has published over 200 peer-reviewed articles and received the Susan G. Komen Brinker Award for Scientific Distinction. In 2016, she was named one of TIME Magazine's 100 Most Influential People in the World.